{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:17:57Z","timestamp":1780550277447,"version":"3.54.1"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Familial hyperaldosteronism type 1 (FH1), previously known as glucocorticoid-remediable aldosteronism, was the first identified monogenic cause of primary aldosteronism. Patients classically develop hypertension at a young age and are at risk of premature vascular complications. A systematic review of FH1 was performed to determine long-term treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted searches with a patient\/population, intervention, comparison and outcomes (PICO) framework using Embase, Medline, PubMed, Scopus, and Web of Science databases to identify patients with FH1 prescribed either no treatment with a minimum 3 months follow-up or medical treatment of at least 3 months duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 99 FH1 cases were identified from 42 studies. Most had early-onset hypertension but variable hypokalemia, hyperaldosteronism, and hyporeninemia. Of the 62 cases with a reported age of FH1 diagnosis, median age was 18 \u00b1 17.6 years old. Of those treated, 72% received a glucocorticoid for long-term treatment compared with 22% receiving a potassium-sparing diuretic. Data on long-term treatment and disease side effects, complications, and outcomes were seldom reported. However, of 20 patients with reported complications, premature vascular complications were evident with the median age of diagnosis for left ventricular hypertrophy and hypertensive retinopathy 15 and 16.5 years old respectively, the youngest age of aortic dissection age 10 years, and those with reported cerebrovascular history had strokes or transient ischemic attacks before age 40 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Major gaps in the literature around FH1 patients\u2019 long-term treatment and disease outcomes still exist. Long-term outcome data are required to help inform clinicians of the best long-term treatment for FH1.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/hypertensionaha.123.21054","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T05:00:35Z","timestamp":1683867635000},"page":"1517-1525","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Systematic Review of Therapeutic Agents and Long-Term Outcomes of Familial Hyperaldosteronism Type 1"],"prefix":"10.1161","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8139-1227","authenticated-orcid":true,"given":"Shu Ting","family":"Tan","sequence":"first","affiliation":[{"name":"Waikato Clinical Campus, University of Auckland, Hamilton, New Zealand (S.T.T., V.B., M.S.E.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Boyle","sequence":"additional","affiliation":[{"name":"Waikato Clinical Campus, University of Auckland, Hamilton, New Zealand (S.T.T., V.B., M.S.E.)."},{"name":"Endocrine Unit, Waikato Hospital, New Zealand (V.B., M.S.E.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0748-2300","authenticated-orcid":true,"given":"Marianne S.","family":"Elston","sequence":"additional","affiliation":[{"name":"Waikato Clinical Campus, University of Auckland, Hamilton, New Zealand (S.T.T., V.B., M.S.E.)."},{"name":"Endocrine Unit, Waikato Hospital, New Zealand (V.B., M.S.E.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/355262a0"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.11150"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094803"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14149"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0128"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1530\/EC-16-0081"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0160"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.9.5978"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30319-4"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.31.1.445"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-27-2-300"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-28-12-1807"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrine1927.66.1_50"},{"key":"e_1_3_3_17_2","first-page":"1109","article-title":"Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone.","volume":"95","author":"Sutherland DJ","year":"1966","unstructured":"Sutherland, DJ, Ruse, JL, Laidlaw, JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J. 1966;95:1109\u20131119.","journal-title":"Can Med Assoc J"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02763-5"},{"key":"e_1_3_3_19_2","volume-title":"In: Joanna briggs institute reviewer\u2019s manual","author":"Moola S","year":"2017","unstructured":"Moola, S, Munn, Z, Tufanaru, C, Aromataris, E, Sears, K, Sfetcu, R, et al. Systematic reviews of etiology and risk. Aromataris, E, Munn, Z, eds. In: Joanna briggs institute reviewer\u2019s manual. The Joanna Briggs Institute; 2017."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199715120-00080"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1997.tb00999.x"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.1210334"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2017571"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-10-813"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.13567"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.6.6651"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7827-11-76"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02966-w"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.782001"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.3109\/02688697.2015.1023775"},{"key":"e_1_3_3_31_2","first-page":"330","article-title":"[Primary hyperaldosteronism suppressed after glucocorticoid administration].","volume":"43","author":"Brzezinska A","year":"1992","unstructured":"Brzezinska, A, Slowinska-Srzednicka, J, Wieteska-Klimczak, A, Wyszynska, T, Januszewicz, P. [Primary hyperaldosteronism suppressed after glucocorticoid administration]. Endokrynol Pol. 1992;43:330\u2013335.","journal-title":"Endokrynol Pol"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.26442\/terarkh2018909115-122"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)67088-5"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.8.8.669"},{"key":"e_1_3_3_35_2","first-page":"69","article-title":"Dexamethasone suppressible hyperaldosteronism: insights into adrenal physiology.","volume":"19","author":"Connell JM","year":"1990","unstructured":"Connell, JM, Jardine, A, Fraser, R. Dexamethasone suppressible hyperaldosteronism: insights into adrenal physiology. Adv Nephrol Necker Hosp. 1990;19:69\u201377.","journal-title":"Adv Nephrol Necker Hosp"},{"key":"e_1_3_3_36_2","first-page":"505","article-title":"Dexamethasone-suppressible hyperaldosteronism: clinical, biochemical and genetic relations.","volume":"9","author":"Connell JM","year":"1995","unstructured":"Connell, JM, Inglis, GC, Fraser, R, Jamieson, A. Dexamethasone-suppressible hyperaldosteronism: clinical, biochemical and genetic relations. J Hum Hypertens. 1995;9:505\u2013509.","journal-title":"J Hum Hypertens"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1988.tb01228.x"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1985.02140100085039"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.33.1.25"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-36-4-715"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.65.3.597"},{"key":"e_1_3_3_42_2","first-page":"52","article-title":"Glucocorticoid remediable aldosteronism: a case report.","volume":"20","author":"Hsieh CJ","year":"1997","unstructured":"Hsieh, CJ, Wang, PW, Liu, JC, Tung, SC, Chien, WY, Lu, YC, Kuo, MC. Glucocorticoid remediable aldosteronism: a case report. Changgeng Yi Xue Za Zhi. 1997;20:52\u201357.","journal-title":"Changgeng Yi Xue Za Zhi"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2014.03.312"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199505000-00011"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1971.00310210056004"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.0990251"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-53-1-158"},{"key":"e_1_3_3_48_2","first-page":"324","article-title":"Familial hyperaldosteronism type 1 in an infant without hypertension: how important could be the early treatment with hydrocortisone?","volume":"84","author":"Martinez-Aguayo A","year":"2015","unstructured":"Martinez-Aguayo, A, Mendoza, C, Loureiro, C, Campino, C, Carvajal, C, Baudrand, R, Rumie, H, Bancalari, R, Garcia, H, Vecchiola, A, et al. Familial hyperaldosteronism type 1 in an infant without hypertension: how important could be the early treatment with hydrocortisone? 54th Annual ESPE. 2015;84:324.","journal-title":"54th Annual ESPE"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.1377"},{"key":"e_1_3_3_50_2","first-page":"1361","article-title":"[Hypertension treatable with glucocorticoids: report of a case].","volume":"125","author":"Montero J","year":"1997","unstructured":"Montero, J, Fardella, C, Mosso, L. [Hypertension treatable with glucocorticoids: report of a case]. Rev Med Chil. 1997;125:1361\u20131365.","journal-title":"Rev Med Chil"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-43-6-1283"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.107.101915"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000918"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-64-1-22"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.9.6834"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.11.4365"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.77.3.8396580"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.11.6159"},{"key":"e_1_3_3_59_2","first-page":"1","article-title":"Non-tumorous \u201cprimary\u201d aldosteronism. I. Type relieved by glucocorticoid (glucocorticoid-remediable aldosteronism).","volume":"101","author":"Salti IS","year":"1969","unstructured":"Salti, IS, Stiefel, M, Ruse, JL, Laidlaw, JC. Non-tumorous \u201cprimary\u201d aldosteronism. I. Type relieved by glucocorticoid (glucocorticoid-remediable aldosteronism). Can Med Assoc J. 1969;101:1\u201310.","journal-title":"Can Med Assoc J"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl706"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1985.tb02640.x"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004670050292"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.123.21054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T19:00:50Z","timestamp":1763578850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.123.21054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.123.21054"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.123.21054","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2023-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}